The Quantellect read.As of Nov 19, 2026, 10 active firms cover Crispr Therapeutics AG: 7 rate it Buy or better, 3 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $45.00 to $110.00 (about 2.4x), a sign of real disagreement on valuation. The average target of $74.30 sits 85% above the current $40.14. The rating mix has stayed broadly stable, with Buy-side ratings easing from 9 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.09 next quarter toward $-3.69 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 active firms
Buy
Strong Buy00%
Buy770%
Neutral330%
Sell00%
Strong Sell00%
Based on 10 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$74.30
+85.1% upside
Average target across 10 active firms as of Nov 19, 2026 vs $40.14 current
Highest Target$110.00
Average Target$74.30
Lowest Target$45.00
Detailed analyst forecasts for CRSP
Showing 1–11 of 11 named analysts shown · 10 active firms in the rating projection
As of Nov 19, 2026, 7 of 10 active firms rate CRSP a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CRSP EPS & revenue forecast
EPS · NEXT QUARTER
$-1.09
Range $-1.33 – $-0.73 · 7 analysts · -15% YoY
Next period, 7 analysts expect Crispr Therapeutics AG to earn $-1.09 a share (range $-1.33 – $-0.73), versus $-1.28 a year earlier. Full-year consensus is $-4.53, growing to $-3.69 the year after.
REVENUE · NEXT QUARTER
$11.4M
Range $300.0K – $42.5M · 7 analysts · +685% YoY
Revenue is expected to reach $11.4M (range $300.0K – $42.5M), +685.3% year-over-year. Full-year consensus is $35.5M, rising to $134.1M next year.
Top analysts covering Crispr Therapeutics AG
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CRSP.
#1
Silvan Tuerkcan
JMP Securities · Rank #69
Buy
$80.00+99.3% to target
Overall win rate
51%
+ Follow
#2
Luca Issi
RBC Capital · Rank #76
Neutral
$50.00+24.6% to target
Overall win rate
49%
+ Follow
#3
Brian Cheng
JP Morgan · Rank #87
Buy
$67.00+66.9% to target
Overall win rate
51%
+ Follow
#4
Geulah Livshits
Chardan Capital · Rank #104
Buy
$76.00+89.3% to target
Overall win rate
43%
+ Follow
#5
Terence Flynn
Morgan Stanley · Rank #222
Sell
$33.00-17.8% to target
Overall win rate
36%
+ Follow
CRSP stock forecast FAQ
What is CRSP's average 12-month price target?+
The 10 active firms with a live target average $74.30 for Crispr Therapeutics AG over the next 12 months, ranging from a $110.00 high to a $45.00 low, as of Nov 19, 2026.
Is CRSP stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 10 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 3 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CRSP?+
The Street-high target is $110.00 (Piper Sandler), and the Street-low is $45.00 (TD Cowen). The average of all 10 active-firm targets is $74.30.
How many active Wall Street firms cover CRSP?+
10 active firms have a recognized rating on Crispr Therapeutics AG as of Nov 19, 2026, and 10 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CRSP?+
Among analysts who currently cover CRSP, Silvan Tuerkcan of JMP Securities has the strongest overall Quantellect track record (Rank #69). Their current call is Buy with a $80.00 target.
What is Crispr Therapeutics AG's projected EPS for next quarter?+
The consensus estimate is $-1.09 per share (range $-1.33 – $-0.73) across 7 analysts. Full-year EPS is projected at $-4.53, rising to $-3.69 the following year.
How much revenue is Crispr Therapeutics AG expected to report next quarter?+
Consensus revenue is $11.4M (range $300.0K – $42.5M). Full-year revenue is projected at $35.5M, growing to $134.1M next year.
Have analysts been upgrading or downgrading CRSP lately?+
As of Nov 19, 2026, 7 of 10 active firms rate CRSP a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CRSP calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.